Drugs / MIRZOTAMAB CLEZUTOCLAX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06934889 | Apr 2025 → Apr 2028 expected | gliosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03595059 | Jul 2018 → Sep 2025 | cancer | AbbVie | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIRZOTAMAB CLEZUTOCLAX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594514 ↗ |
| Known as | ABBV-155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06934889 ↗ |
| Route | Intravenous | “will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.” NCT06934889 ↗ |